摘要
作为一个新长效抗胆碱能药物,格隆溴铵已被许多临床研究证实能在5min内起效且作用时间达24h,能减少慢性阻塞性肺病患者的呼吸急促、病情恶化和急救药物的使用,有效地改善肺功能和生活质量以及提高运动耐受性,同时耐受性和安全性良好,可用于治疗中、重度慢性阻塞性肺病。
As a new long-acting anti-cholinergic agent, glycopyrronium bromide has shown that it has a fast-onset of action (within 5 rain after inhalation) and 24-hour bronchodilatory effect by many clinical studies. The shortness of breath, exacerbations and the use of rescue medication can be reduced and lung function, quality of life and exercise tolerance can be effectively improved as well when glycopyrronium bromide is used in the treatment of patients with chronic obstructive pulmonary disease (COPD). Moreover, it shows a good safety profile and is generally well tolerated when used for the treatment of adult patients with moderate to severe COPD.
出处
《上海医药》
CAS
2013年第15期10-12,共3页
Shanghai Medical & Pharmaceutical Journal
关键词
格隆溴铵
慢性阻塞性肺病
抗胆碱能药物
glycopyrronium bromide
chronic obstructive pulmonary disease
anti-cholinergic agent